Rotarod Impairment: Catalepsy-Like Screening Test for Antipsychotic Side Effects

REFERENCES

• Ahlenius S., Hillegaart V. Involvement of extrapyramidal motor mechanisms in the suppression of locomotor activity by antipsychotic drugs: A comparison between the effects produced by pre- and post-synaptic inhibition of dopaminergic neurotransmission. Pharmacology Biochemistry & Behaviour 1986; 24: 1409–1415
   PubMed Web of Science ®Google Scholar
• Andersen H. L., Kilpatrick I. C. Prevention by (+/−)-8-hydroxy-2-(di-n-propylamino)tetralin of both catalepsy and the rises in rat striatal dopamine metabolism caused by haloperidol. British Journal of Pharmacology 1996; 118: 421–427
   PubMedGoogle Scholar
• Arnt J., Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998; 18: 63–101
   PubMed Web of Science ®Google Scholar
• Bardin L., Kleven M. S., Barret-Grevoz C., Depoortere R., Newman-Tancredi A. Antipsychotic-like vs. cataleptogenic actions in mice of novel antipsychotics having D(2) antagonist and 5-HT(1A) agonist properties. Neuropsychopharmacology 2006; 31: 1869–1879
   PubMedGoogle Scholar
• Barnes D. E., Robinson B., Csernansky J. G., Bellows E. P. Sensitization versus tolerance to haloperidol-induced catalepsy: Multiple determinants. Pharmacology Biochemistry & Behaviour 1990; 36: 883–887
   PubMedGoogle Scholar
• Bristow L. J., Collinson N., Cook G. P., Curtis N., Freedman S. B., Kulagowski J. J., et al. L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioural tests. The Journal of Pharmacology and Experimental Therapeutics 1997; 283: 1256–1263
   PubMedGoogle Scholar
• Correll C. U., Leucht S., Kane J. M. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. American Journal of Psychiatry 2004; 161: 414–425
   PubMed Web of Science ®Google Scholar
• Delcker A., Schoon M. L., Oczkowski B., Gaertner H. J. Amisulpride versus haloperiol in treatment of schizophrenic patients—results of a double-blind study. Pharmacopsychiatry 1990; 23: 125–130
   PubMedGoogle Scholar
• El Ela A. A., Hartter S., Schmitt U., Hiemke C., Spahn-Langguth H., Langguth P. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds—implications for pharmacokinetics of selected substrates. Journal of Pharmacy & Pharmacology 2004; 56: 967–975
   PubMed Web of Science ®Google Scholar
• Essig E. C., Kilpatrick I. C. Influence of acute and chronic haloperidol treatment on dopamine metabolism in the rat caudate-putamen, prefrontal cortex and amygdala. Psychopharmacology 1991; 104: 194–200
   PubMedGoogle Scholar
• Green B. Focus on aripiprazole. Current Medical Research & Opinion 2004; 20: 207–213
   PubMed Web of Science ®Google Scholar
• Hoyer D., Hannon J. P., Martin G. R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacology Biochemistry & Behaviour 2002; 71: 533–554
   PubMed Web of Science ®Google Scholar
• Kelly M. A., Rubinstein M., Phillips T. J., Lessov C. N., Burkhart-Kasch S., Zhang G., et al. Locomotor activity in D2 dopamine receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations. Journal of Neuroscience 1998; 18: 3470–3479
   PubMed Web of Science ®Google Scholar
• Kikuchi T., Tottori K., Uwahodo Y., Hirose T., Miwa T., Oshiro Y., et al. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. The Journal of Pharmacology and Experimental Therapeutics 1995; 274: 329–336
   PubMed Web of Science ®Google Scholar
• Köhler C., Ogren S. O., Haglund L., Angeby T. Regional displacement by sulpiride of [3H]spiperone binding in vivo biochemical and behavioural evidence for a preferential action of limbic and nigral dopamine receptors. Neuroscience Letters 1979; 13: 51–56
   PubMedGoogle Scholar
• Korpi E. R., Koikkalainen P., Vekovischeva O. Y., Makela R., Kleinz R., Uusi-Oukari M., et al. Cerebellar granule-cell-specific GABAA receptors attenuate benzodiazepine-induced ataxia: Evidence from alpha 6-subunit-deficient mice. European Journal of Neuroscience 1999; 11: 233–240
   PubMedGoogle Scholar
• Kralic J. E., O’Buckley T. K., Khisti R. T., Hodge C. W., Homanics G. E., Morrow A. L. GABA(A) receptor alpha-1 subunit deletion alters receptor subtype assembly, pharmacological, and behavioral responses to benzodiazepines and zolpidem. Neuropharmacology 2002; 43: 685–694
   PubMed Web of Science ®Google Scholar
• Marder S. R., McQuade R. D., Stock E., Kaplita S., Marcus R., Safferman A. Z., et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophrenia Reserch 2003; 61: 123–136
   PubMed Web of Science ®Google Scholar
• Meltzer H. Y., Li Z., Kaneda Y., Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2003; 27: 1159–1172
   PubMed Web of Science ®Google Scholar
• Mishima K., Tanoue A., Tsuda M., Hasebe N., Fukue Y., Egashira N., et al. Characteristics of behavioural abnormalities in alpha1d-adrenoceptors deficient mice. Behavioural Brain Research 2004; 152: 365–373
   PubMedGoogle Scholar
• Nakai S., Hirose T., Uwahodo Y., Imaoka T., Okazaki H., Miwa T., et al. Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone. European Journal of Pharmacology 2003; 472: 89–97
   PubMedGoogle Scholar
• Perrault G. H., Depoortere R., Morel E., Sanger D. J., Scatton B. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. The Journal of Pharmacology and Experimental Therapeutics 1997; 280: 73–82
   PubMed Web of Science ®Google Scholar
• Pertwee R. G. The ring test: A quantitative method for assessing the “cataleptic” effect of cannabis in mice. British Journal of Pharmacology 1972; 46: 753–763
   PubMedGoogle Scholar
• Sanberg P. R. Haloperidol-induced catalepsy is mediated by postsynaptic dopamine receptors. Nature 1980; 284: 472–473
   PubMed Web of Science ®Google Scholar
• Schoemaker H., Claustre Y., Fage D., Rouquier L., Chergui K., Curet O., et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. The Journal of Pharmacology and Experimental Therapeutics 1997; 280: 83–97
   PubMed Web of Science ®Google Scholar
• Stanley J. L., Lincoln R. J., Brown T. A., McDonald L. M., Dawson G. R., Reynolds D. S. The mouse beam-walking assay offers improved sensitivity over the mouse rotarod in determining motor coordination deficits induced by benzodiazepines. Journal of Psychopharmacology 2005; 19: 221–227
   PubMed Web of Science ®Google Scholar
• Stone E. A., Rosengarten H., Lin Y., Quatermain D. Pharmacological blockade of brain alpha1-adrenoceptors as measured by ex vivo [3H] prazosin binding is correlated with behavioural immobility. European Journal of Pharmacology 2001; 420: 97–102
   PubMedGoogle Scholar
• Tada M., Shirakawa K., Matsuoka N., Mutoh S. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine. Psychopharmacology 2004; 176: 94–100
   PubMedGoogle Scholar
• Tsujikawa K., Dan Y., Nogawa K., Sato H., Yamada Y., Murakami H., et al. Potentiation of domperidone-induced catalepsy by a P-glycoprotein inhibitor, cyclosporin A. Biopharmacology and Drug Disposition 2003; 24: 105–114
   PubMedGoogle Scholar
• Wadenberg M. -L. G., Kapur S., Soliman A., Jones C., Vaccarino F. Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology 2000; 150: 422–479
   PubMed Web of Science ®Google Scholar
• Zivkovic B., Guidotti A., Revuelta A., Costa E. Effect of thioridazine, clozapine and other antipsychotics on the kinetic state of tyrosine hydroxylase and on the turnover rate of dopamine in striatum and nucleus accumbens. The Journal of Pharmacology and Experimental Therapeutics 1975; 194: 37–46
   PubMed Web of Science ®Google Scholar